VALN
HealthcareValneva SE
$8.85
$-0.11 (-1.17%)
Jan 5, 2026
Price History (1Y)
Analysis
Valneva SE is a biotechnology company operating in the healthcare sector with 713 employees. The company has a market capitalization of $764.46M and generated revenue of $179.91M in the trailing twelve months (TTM). Valneva's industry segment is characterized by companies that develop and commercialize novel treatments, vaccines, and diagnostic tools. The company's financial health is marked by significant losses, with net income amounting to -$102,160,000 in the TTM period. The operating margin and profit margin stand at -127.0% and -56.8%, respectively, while the gross margin is -2.1%. Valneva has a cash balance of $143.46M but carries significant debt of $195.84M, resulting in a debt-to-equity ratio of 130.15. Valuation metrics for Valneva SE include a forward price-to-earnings (P/E) ratio of -8.12 and an enterprise value-to-EBITDA ratio of -28.92. The company's revenue growth rate over the past year is -35.8%, while its earnings growth rate is not available. Dividend information for Valneva SE includes a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Visit website →Key Statistics
- Market Cap
- $764.46M
- P/E Ratio
- N/A
- 52-Week High
- $12.25
- 52-Week Low
- $4.20
- Avg Volume
- 25.63K
- Beta
- 1.19
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- France
- Employees
- 713